Navigation Links
Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
Date:11/13/2012

CHAPEL HILL, N.C., Nov. 13, 2012 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that it has raised $28 million in a Series B financing led by OrbiMed Advisors.  New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates (NEA) and The Aurora Funds in the financing. Proceeds from this latest round will be used to further advance Cardioxyl's second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart failure.  In conjunction with OrbiMed's role as lead investor in this funding round, OrbiMed Venture Partners Peter Thompson, M.D., and Anthony G. Johnson, M.D., have joined the Cardioxyl Board of Directors.  Bill Harrington, M.D., led the financing for Osage University Partners.

"OrbiMed has a strong track record of identifying innovative and successful companies within the healthcare industry. The firm's commitment, along with that of Osage, NEA and Aurora, creates an outstanding investor syndicate," said Chris Kroeger, M.D., President and Chief Executive Officer of Cardioxyl. "We are also very pleased to welcome Peter Thompson and Tony Johnson to the Cardioxyl Board. Their extensive drug development and leadership experience in the pharmaceutical industry will be invaluable as we advance HNO drug candidates to help improve the health and quality of life for patients with heart failure."

Peter Thompson, M.D., is a Venture Partner with OrbiMed with over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals; co-founded Cleave BioSciences; serves on the Boards of Cleave, Anthera, Methylgene, Principia Biosciences, and Response Biomedical; and previously served as an executive of Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

"Cardioxyl's HNO donor programs represent a unique and highly differentiated approach to treating heart failure, with a significant body of human clinical experience," said Dr. Thompson. "I look forward to joining the Cardioxyl Board and helping to advance this novel therapy for a devastating disease that has seen little innovation in clinical practice over the past decade."

Anthony G. Johnson, M.D., M.P.H., M.B.B.S., F.R.A.C.P., is also an OrbiMed Venture Partner with more than 20 years of pharmaceutical industry leadership experience. Dr. Johnson led exploratory clinical development as Vice President, Discovery Medicine Clinical Pharmacology at Bristol-Myers Squibb and was on the executive team of a Center of Excellence for Drug Discovery responsible for multiple therapeutic areas at GlaxoSmithKline. He established the James Lance GlaxoWelcome Medicines Research Unit and had a tenured academic appointment at Queensland University, where he completed extensive clinical research. He is a fellow of the Royal Australasian College of Physicians, and is board certified in internal medicine, geriatric medicine, and clinical pharmacology with 18 years of broad clinical experience.

"Cardioxyl has an exciting opportunity to impact heart failure, a disease with a high degree of unmet medical need," said Dr. Johnson. "The pharmacological effects anticipated from an HNO donor, namely improved cardiac relaxation, combined with enhanced cardiac contractility and peripheral vasodilation, can address a broad spectrum of the physiologic abnormalities observed in this disorder."

About Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... Charlotte, NC (PRWEB) , ... December 08, 2016 ... ... repeal Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass ... A story movement gives people ongoing opportunities to share their unfortunate experiences; such ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally ... commercial clients in the northern Alabama and Georgia regions, is embarking on a ... Nobis Works has built a network of support and education facilities to develop ...
Breaking Medicine News(10 mins):